30,465 Shares in Kenvue Inc. (NYSE:KVUE) Acquired by Global Assets Advisory LLC

Global Assets Advisory LLC bought a new stake in Kenvue Inc. (NYSE:KVUE) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 30,465 shares of the company’s stock, valued at approximately $654,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in KVUE. Steph & Co. grew its stake in shares of Kenvue by 8.3% in the first quarter. Steph & Co. now owns 24,690 shares of the company’s stock valued at $530,000 after buying an additional 1,890 shares in the last quarter. Douglas Lane & Associates LLC grew its holdings in shares of Kenvue by 18.5% in the 1st quarter. Douglas Lane & Associates LLC now owns 464,893 shares of the company’s stock worth $9,977,000 after acquiring an additional 72,662 shares during the period. Gulf International Bank UK Ltd grew its holdings in shares of Kenvue by 0.9% in the 1st quarter. Gulf International Bank UK Ltd now owns 153,558 shares of the company’s stock worth $3,295,000 after acquiring an additional 1,330 shares during the period. Financiere des Professionnels Fonds d investissement inc. grew its holdings in shares of Kenvue by 15.9% in the 1st quarter. Financiere des Professionnels Fonds d investissement inc. now owns 176,027 shares of the company’s stock worth $3,778,000 after acquiring an additional 24,182 shares during the period. Finally, Park Avenue Securities LLC grew its holdings in shares of Kenvue by 11.1% in the 1st quarter. Park Avenue Securities LLC now owns 36,322 shares of the company’s stock worth $779,000 after acquiring an additional 3,625 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Down 0.9 %

Shares of Kenvue stock opened at $18.42 on Friday. The business has a 50-day moving average of $19.22 and a 200-day moving average of $20.00. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.99 and a quick ratio of 0.68. The company has a market capitalization of $35.27 billion and a PE ratio of 23.62. Kenvue Inc. has a 1-year low of $17.75 and a 1-year high of $26.66.

Kenvue (NYSE:KVUE) last announced its earnings results on Tuesday, May 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.03. The company had revenue of $2.89 billion during the quarter, compared to the consensus estimate of $3.79 billion. Kenvue had a return on equity of 21.06% and a net margin of 9.63%. The firm’s quarterly revenue was down 24.9% compared to the same quarter last year. As a group, equities analysts forecast that Kenvue Inc. will post 1.17 EPS for the current fiscal year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 22nd. Investors of record on Wednesday, May 8th were issued a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 4.34%. The ex-dividend date of this dividend was Tuesday, May 7th. Kenvue’s dividend payout ratio is currently 102.56%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on KVUE shares. Sanford C. Bernstein started coverage on Kenvue in a report on Thursday, April 11th. They issued an “underperform” rating and a $18.00 price target on the stock. Citigroup reiterated a “neutral” rating and set a $21.00 target price on shares of Kenvue in a report on Tuesday, May 28th. HSBC increased their target price on Kenvue from $20.00 to $21.00 and gave the stock a “hold” rating in a research report on Wednesday, May 8th. The Goldman Sachs Group assumed coverage on Kenvue in a research report on Friday, March 1st. They issued a “neutral” rating and a $20.00 target price on the stock. Finally, William Blair assumed coverage on Kenvue in a research report on Wednesday, April 3rd. They issued a “market perform” rating on the stock. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, Kenvue currently has an average rating of “Hold” and an average target price of $23.09.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.